Apogee Therapeutics, Inc. (APGE)
NASDAQ:APGE
Want to see APGE full AI Analyst Report?
Top Page
Apogee Therapeutics
(NASDAQ:APGE)
Select Model
Select Model
Rating:63Neutral
Price Target:
$88.00
▼(-4.56% Downside)
Action:Reiterated
Date:05/27/26
The score is driven primarily by a strong balance sheet and multiple positive clinical/financing events that improve runway and de-risk near-term execution. Offsetting these strengths are the lack of revenue, materially widening losses, and significant cash burn, while technicals are supportive but not strongly bullish and valuation offers limited support given negative earnings.
Positive Factors
Balance-sheet strength
Very low leverage and large equity/assets growth from successful capital raises give Apogee durable funding flexibility. This reduces refinancing risk, supports multi-year Phase 3 programs and commercialization planning, and lowers near-term dilution pressure while R&D executes.
Negative Factors
Pre-revenue status
Apogee has no product sales and relies on financing, milestones, or partnerships for cash flow. Until commercialization, predictable revenue streams are absent, making financial stability contingent on successful trials, partner deals, or capital markets access over the next 2–6+ months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Very low leverage and large equity/assets growth from successful capital raises give Apogee durable funding flexibility. This reduces refinancing risk, supports multi-year Phase 3 programs and commercialization planning, and lowers near-term dilution pressure while R&D executes.
Read all positive factors
Apogee Therapeutics (APGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.19B
Dividend YieldN/A
Average Volume (3M)785.29K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS Growth-22.17%
CountryUS
Employees196
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.33
Shares Outstanding61,902,733
10 Day Avg. Volume1,105,241
30 Day Avg. Volume785,288
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.37K
Enterprise Value/Ebitda-15.61
Forecast
1Y Price Target
$118.00Price Target Upside27.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-4.43
Revenue Forecast (FY)N/A
Apogee Therapeutics Business Overview & Revenue Model
Company Description
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indic...
How the Company Makes Money
Apogee Therapeutics is a clinical-stage company and, based on publicly available information, it does not have a commercialized product portfolio generating recurring product sales. As a result, its revenue, when present, would primarily come from...
Apogee Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -408.00K | -1.42M | 0.00 | 0.00 | 0.00 |
| EBITDA | -297.34M | -284.18M | -216.68M | -74.97M | -39.78M |
| Net Income | -274.62M | -255.84M | -182.15M | -83.98M | -39.78M |
Balance Sheet | |||||
| Total Assets | 1.29B | 937.13M | 753.95M | 401.40M | 152.06M |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 730.19M | 520.65M | 395.46M | 151.89M |
| Total Debt | 8.05M | 8.85M | 11.83M | 2.03M | 0.00 |
| Total Liabilities | 37.86M | 33.25M | 37.16M | 21.49M | 9.98M |
| Stockholders Equity | 1.26B | 903.88M | 716.79M | 379.91M | 142.07M |
Cash Flow | |||||
| Free Cash Flow | -235.37M | -232.60M | -172.33M | -74.93M | -16.43M |
| Operating Cash Flow | -234.54M | -227.45M | -171.17M | -74.76M | -16.43M |
| Investing Cash Flow | -227.91M | -179.57M | -300.46M | -273.91M | 0.00 |
| Financing Cash Flow | 807.03M | 396.49M | 495.11M | 315.39M | 168.32M |
Apogee Therapeutics Technical Analysis
Negative
92.20
Price Trends
83.07
Negative
77.36
Positive
66.20
Positive
Market Momentum
-0.97
Positive
45.20
Neutral
43.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APGE, the sentiment is Negative. The current price of 92.2 is above the 20-day moving average (MA) of 81.73, above the 50-day MA of 83.07, and above the 200-day MA of 66.20, indicating a neutral trend. The MACD of -0.97 indicates Positive momentum. The RSI at 45.20 is Neutral, neither overbought nor oversold. The STOCH value of 43.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APGE.
Apogee Therapeutics Risk Analysis
Apogee Therapeutics disclosed 70 risk factors in its most recent earnings report. Apogee Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Apogee Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $5.50B | 231.78 | 46.82% | ― | 1936.66% | ― | |
63 Neutral | $6.19B | -20.12 | -32.64% | ― | ― | -22.17% | |
57 Neutral | $2.59B | -18.33 | -13.96% | ― | 3118.14% | 55.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.97B | -6.89 | -64.55% | ― | -12.76% | -26.75% | |
48 Neutral | $1.75B | -3.89 | -34.11% | ― | 78.34% | -161.91% |
* Healthcare Sector Average
APGE
Apogee Therapeutics
79.30
42.97
118.28%
AGIO
Agios Pharma
28.00
-4.63
-14.19%
OCUL
Ocular Therapeutix
8.93
0.82
10.11%
LQDA
Liquidia Technologies
58.75
41.88
248.22%
IDYA
IDEAYA Biosciences
28.94
7.72
36.38%
Apogee Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Apogee Advances Zumilokibart After Positive Phase 2 Results
Positive
May 27, 2026
On May 27, 2026, Apogee Therapeutics reported that Part B of its Phase 2 APEX trial in moderate-to-severe atopic dermatitis met all primary and key secondary endpoints, with mid-dose zumilokibart achieving an EASI-75 response in 65.9% of patients ...
Business Operations and StrategyPrivate Placements and Financing
Apogee Therapeutics Secures Major Non-Dilutive Blackstone Financing
Positive
May 27, 2026
On May 26, 2026, Apogee Therapeutics entered a revenue participation agreement with Blackstone Life Sciences affiliate Annapurna Aggregator L.P., securing an initial $100 million synthetic royalty tranche tied to future global sales of its anti-IL...
Business Operations and StrategyExecutive/Board Changes
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift
Neutral
Apr 24, 2026
On April 21, 2026, Apogee Therapeutics, Inc. announced that board members Andrew Gottesdiener, M.D., and Peter Harwin had notified the company of their intention to resign from its Board of Directors effective May 11, 2026. The company stated that...
Private Placements and FinancingRegulatory Filings and Compliance
Apogee Therapeutics Prices Upsized Public Equity Offering
Positive
Mar 25, 2026
On March 24, 2026, Apogee Therapeutics, Inc. entered into an underwriting agreement with a syndicate led by Jefferies, TD Securities, Stifel and Guggenheim Securities to sell 5,000,000 shares of its common stock at a public offering price of $70.0...
Business Operations and StrategyProduct-Related Announcements
Apogee Therapeutics Announces Positive Phase 2 APEX Maintenance Data
Positive
Mar 23, 2026
On March 23, 2026, Apogee Therapeutics reported positive 52-week maintenance data from Part A of its Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis, showing durable and deepening clinical responses with 3- and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.